Vaccines are an extraordinary achievement of medicine. Their success, however, does not put every product, manufacturer or recommendation beyond scrutiny. CGHA’s research, Vaccines and the Changing Burden of Disease, assesses vaccination through the outcomes it delivers: disease and disability prevented, injuries caused, and the quality of the evidence behind each judgment.
The research examines British and American experience within a global context. It begins with the decline in infectious-disease mortality before many vaccines became available, recognizing the contributions of living conditions and medical care. It then asks what vaccination subsequently added, including prevention of paralysis, congenital injury, invasive bacterial disease and hospitalization. Falling deaths before vaccine introduction do not, by themselves, explain away these later gains.
Benefits must be described in terms that patients can understand. A large relative reduction can accompany a modest absolute benefit when the underlying risk is low. Protection against severe illness is different from protection against infection or transmission. Age, prior infection, health status and time since vaccination can materially change the assessment. The research therefore distinguishes established childhood programs from seasonal vaccination and additional COVID doses.
The global comparison also matters. Where infection remains dangerous and treatment is difficult to obtain, preventing disease can deliver especially large survival gains. The research examines published estimates of those benefits while distinguishing modeled outcomes from directly observed counts. It does not assume that the same intervention has an identical value in every country.
Safety receives the same scrutiny. Recognized injuries belong in the assessment even when population benefits remain strongly positive. Suspected events require investigation, but an illness occurring after vaccination does not establish causation. Commercial sponsorship, publication practices and institutional incentives warrant examination without making either official sources or dissident critics automatically authoritative.
Political polarization complicates that work. Pew’s 2025 research documents a substantial partisan gap in confidence in childhood vaccines, alongside differences within each party. The research argues that selective hesitation, objections to mandates and wholesale rejection of vaccination should be distinguished. Its Cambridge and Montgomery County comparison explores these questions descriptively; incomplete methods and unreconciled category totals limit the conclusions that can be drawn from those local aggregates.
Liability protection presents a further accountability challenge. The United States has separate compensation arrangements for covered routine vaccines and COVID countermeasures. The former was established partly to maintain vaccine supply. COVID vaccines receive broad, conditional PREP Act liability protection, with an exception for willful misconduct, and injury claims go through the countermeasure compensation program. That scheme provides fewer procedural protections than the ordinary vaccine scheme, including no judicial appeal of injury determinations and no payment of legal fees.
The research’s emphasis on accountability points to a wider concern: when protection for manufacturers appears stronger than redress for patients, distrust can spread beyond a disputed vaccine to pharmaceutical medicine generally. This is a plausible institutional mechanism, rather than a causal finding established by the local data. Such distrust can itself damage health when it displaces assessment of an intervention’s actual merits.
Finally, clinical benefit and compulsory policy require separate arguments. A useful vaccine does not automatically justify requiring it. The research places the burden on governments to demonstrate the additional benefit and proportionality of a specific restriction, while acknowledging evidence that some targeted requirements can protect vulnerable people.
The resulting agenda is practical: preserve effective prevention, report benefits and harms transparently, investigate safety concerns promptly, provide fair compensation and revise policies as evidence changes. Vaccines should earn confidence through the outcomes they deliver. Political identity and institutional reputation cannot substitute for that evidence.
The full research examines these questions disease by disease, with historical comparisons, benefit and harm assessments, source links and a glossary.
Read the full CGHA report, including its figures, tables and references.
